Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-6
M. Zhang, Xue Shan, Haifeng Lin, Mingyue Zhu, Mengsen Li
{"title":"Tumor-associated Macrophages (TAMs) is an Available Biotarget for Therapeutic of Hepatocellular Carcinoma","authors":"M. Zhang, Xue Shan, Haifeng Lin, Mingyue Zhu, Mengsen Li","doi":"10.37155/2717-5278-0301-6","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-6","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"65 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128724884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0202-2
Dia Roy, S. Bose, S. Dutta, G. Sa
The infiltration of immune cells in the tumor micro-environment is well-documented in cancer patients and the resultant complex interactions are determinants of disease prognosis. Consequently, a proper understanding of this interplay is essential for the development and advancement of therapeutic strategies as well as novel prognostic markers. The co-existence of immune cells with the tumor is often accompanied by an impaired immune response that creates a tumor-promoting micro-environment. T-cell mediated immunity forms the major branch of the immune system that is required to mount an effective response against nascent tumors. Major research in the last few decades indicates that a potent source of immunosuppressive cellular and molecular networks prevailing at the site of tumor is mediated by dysfunctional and defective responses mediated by T cell thereby redirecting and reshaping the destiny of T cell and promoting tumor progression. In this review, we aim to summarize the breakthrough advances in recent years that help us gain a better understanding of the immunosuppressive networks resulting from T-cell anergy, exhaustion, senescence and presence of Treg cells in the tumor micro-environment. We also focus on recent discoveries regarding advance in the Th17 balance, polyfunctionality of T cells as well as T cell stemness that improve our perception of the tumor-immunity interactions. We try to emphasize how such information has an impact on therapeutic development and the clinical outcome of the patients.
{"title":"The Paradigm of T Cells in Shaping Tumor Microenvironment","authors":"Dia Roy, S. Bose, S. Dutta, G. Sa","doi":"10.37155/2717-5278-0202-2","DOIUrl":"https://doi.org/10.37155/2717-5278-0202-2","url":null,"abstract":"The infiltration of immune cells in the tumor micro-environment is well-documented in cancer patients and the resultant complex interactions are determinants of disease prognosis. Consequently, a proper understanding of this interplay is essential for the development and advancement of therapeutic strategies as well as novel prognostic markers. The co-existence of immune cells with the tumor is often accompanied by an impaired immune response that creates a tumor-promoting micro-environment. T-cell mediated immunity forms the major branch of the immune system that is required to mount an effective response against nascent tumors. Major research in the last few decades indicates that a potent source of immunosuppressive cellular and molecular networks prevailing at the site of tumor is mediated by dysfunctional and defective responses mediated by T cell thereby redirecting and reshaping the destiny of T cell and promoting tumor progression. In this review, we aim to summarize the breakthrough advances in recent years that help us gain a better understanding of the immunosuppressive networks resulting from T-cell anergy, exhaustion, senescence and presence of Treg cells in the tumor micro-environment. We also focus on recent discoveries regarding advance in the Th17 balance, polyfunctionality of T cells as well as T cell stemness that improve our perception of the tumor-immunity interactions. We try to emphasize how such information has an impact on therapeutic development and the clinical outcome of the patients.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131885003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-1
G. Aurilio, M. Santoni, A. Cimadamore, E. Verri, R. Montironi
Treatment algorithm in metastatic renal cell carcinoma (RCC) patients has rapidly evolved during the last decade, and determining the prognosis of these patients has become a priority step for correctly planning the treatment. In the present article, we firstly address the most currently used prognostic models and how they have changed the treatment algorithm in routine clinical care; then we assess whether patient selection may be improved in the firstline treatment and the usefulness of a prognostic model following first-line failure; ultimately we culminate in new clinical and molecular prognostic factors under investigation. For this last issue, biomarkers for immunotherapy and angiogenesis inhibitors, as well as biomarkers for liquid analysis and for clinical obesity are presented.
{"title":"Prognostic Biomarkers in Patients with Renal Cell Carcinoma: Where are We Going from Here?","authors":"G. Aurilio, M. Santoni, A. Cimadamore, E. Verri, R. Montironi","doi":"10.37155/2717-5278-0301-1","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-1","url":null,"abstract":"Treatment algorithm in metastatic renal cell carcinoma (RCC) patients has rapidly evolved during the last decade, and determining the prognosis of these patients has become a priority step for correctly planning the treatment. In the present article, we firstly address the most currently used prognostic models and how they have changed the treatment algorithm in routine clinical care; then we assess whether patient selection may be improved in the firstline treatment and the usefulness of a prognostic model following first-line failure; ultimately we culminate in new clinical and molecular prognostic factors under investigation. For this last issue, biomarkers for immunotherapy and angiogenesis inhibitors, as well as biomarkers for liquid analysis and for clinical obesity are presented.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125147554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-5
Pan Gu, Di Li, Gang Xu, Yingnan Sun, Minghua Wu
{"title":"Gut Microbiota: The Servant of Human Being and the Accessary of Tumorigenesis","authors":"Pan Gu, Di Li, Gang Xu, Yingnan Sun, Minghua Wu","doi":"10.37155/2717-5278-0301-5","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-5","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"28 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122631498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-2021-03-02-3
Stephan Ohlinger
{"title":"Clinical Analysis of Areola Small Incision Surgery for Benign Breast Tumors","authors":"Stephan Ohlinger","doi":"10.37155/2717-5278-2021-03-02-3","DOIUrl":"https://doi.org/10.37155/2717-5278-2021-03-02-3","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126430750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-2021-03-02-5
Jonathan Yeoh
{"title":"Correlation between Hp Infection with Clinicopathological Features, Tumor Markers, Oncogene Expression in Patients with Gastric Cancer","authors":"Jonathan Yeoh","doi":"10.37155/2717-5278-2021-03-02-5","DOIUrl":"https://doi.org/10.37155/2717-5278-2021-03-02-5","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122699141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-2021-03-02-4
Tian Dong
{"title":"The Effect of Balanced Analgesia with Sufentanil and Flurbiprofen Axetil in Patients with Cervical Cancer after Open Surgery","authors":"Tian Dong","doi":"10.37155/2717-5278-2021-03-02-4","DOIUrl":"https://doi.org/10.37155/2717-5278-2021-03-02-4","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"23 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124874623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0202-4
A. Shaaban, A. Mohanty, Yousef Abo Eseud, J. Albarrak
Colorectal cancer (CRC) is the third-largest cancer in the world and has the second-highest mortality rate, characterized by poor prognosis and high metastasis. The early symptoms of CRC are mostly inconspicuous and it is usually diagnosed in the advanced stages. Nearly half of the patients diagnosed with metastatic colorectal cancer (mCRC) are inoperable and have high chances of recurrence and metastasis. Combination therapy with cetuximab and chemotherapy is considered the first-line treatment for mCRC. In patients with Kirsten RAt Sarcoma wild-type mCRC, re-challenge and maintenance therapy with cetuximab was found to be beneficial. However, the disease progression is inevitable. This paper discusses three different cases of metastatic adenocarcinoma in the colon and rectum treated with the re-introduction and re-challenge of cetuximab in combination with chemotherapy. The treatment was found to be effective in treating mCRC in later lines of therapy where treatment options are scarce.
{"title":"Role of Cetuximab Re-introduction and Re-challenge in Later Lines of Treatment in Metastatic Colorectal Cancer: A Case Series","authors":"A. Shaaban, A. Mohanty, Yousef Abo Eseud, J. Albarrak","doi":"10.37155/2717-5278-0202-4","DOIUrl":"https://doi.org/10.37155/2717-5278-0202-4","url":null,"abstract":"Colorectal cancer (CRC) is the third-largest cancer in the world and has the second-highest mortality rate, characterized by poor prognosis and high metastasis. The early symptoms of CRC are mostly inconspicuous and it is usually diagnosed in the advanced stages. Nearly half of the patients diagnosed with metastatic colorectal cancer (mCRC) are inoperable and have high chances of recurrence and metastasis. Combination therapy with cetuximab and chemotherapy is considered the first-line treatment for mCRC. In patients with Kirsten RAt Sarcoma wild-type mCRC, re-challenge and maintenance therapy with cetuximab was found to be beneficial. However, the disease progression is inevitable. This paper discusses three different cases of metastatic adenocarcinoma in the colon and rectum treated with the re-introduction and re-challenge of cetuximab in combination with chemotherapy. The treatment was found to be effective in treating mCRC in later lines of therapy where treatment options are scarce.","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"83 2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131010841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0202-3
K. Rygiel
{"title":"To Use or not to Use Anticoagulation in Patients with Advanced Malignancies? – This is the Question","authors":"K. Rygiel","doi":"10.37155/2717-5278-0202-3","DOIUrl":"https://doi.org/10.37155/2717-5278-0202-3","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128112899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.37155/2717-5278-0301-3
E. Bahattab, Khalid Shah, M. Fallatah
{"title":"New Approaches for T Cell Immunomodulation","authors":"E. Bahattab, Khalid Shah, M. Fallatah","doi":"10.37155/2717-5278-0301-3","DOIUrl":"https://doi.org/10.37155/2717-5278-0301-3","url":null,"abstract":"","PeriodicalId":348972,"journal":{"name":"Trends in Oncology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114786140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：